CC-90009 (CC90009; Eragidomide) is a novel and potent modulator of cereblon (CRBN), which is part of the cullin 4-RING E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase; CUL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities.

SZL P1-41 is a Skp2 inhibitor that phenocopies the effects observed upon genetic Skp2 deficiency, such as suppressing survival, Akt-mediated glycolysis as well as triggering p53-independent cellular senescence.

CC-885 (CC885) is a novel and potent cereblon (CRBN) modulator with potent antitumour activity, it acts by the degradation of GSPT1 and was demonstrated to mediate antitumor effects through the recruitment and degradation of G1 to S phase transition 1 protein (GSPT1).

Iberdomide (also known as CC-220) is a novel and potent cereblon (CRBN) modulator with an IC50 of 60 nM and can be potentially used for the treatment of systemic lupus erythematosus.

Skp2 inhibitor C1 (also known as SKPin C1) is a specific and selective small-molecule inhibitor of Skp2-mediated p27 degradation, it selectively inhibited Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts.

Smurf1-IN-A01 is a novel, potent, high affinity and selective inhibitor of E3 ubiquitin-protein ligase Smurf1 (Smad ubiquitination regulatory factor-1) with Kd value of 3.7 nM.

VL285 is a potent VHL ligand, degrading HaloTag7 fusion proteins.

Avadomide HCl, the hydrochloride salt of Avadomide (formerly known as CC-122) with improved water solubility, is a novel, orally available pleiotropic pathway modulator with potential with anticancer and immunomodulatory activity.

Avadomide (formerly known as CC-122) is a novel, orally available pleiotropic pathway modulator with potential with anticancer and immunomodulatory activity.

PRT4165 (NSC600157) is a potent and selective inhibitor of the PRC1 (polycomb repressive complex 1)-mediated H2A ubiquitylation with potential anticancer activity.